104 related articles for article (PubMed ID: 11281957)
21. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade.
Heresco-Levy U
Int J Neuropsychopharmacol; 2000 Sep; 3(3):243-258. PubMed ID: 11343602
[TBL] [Abstract][Full Text] [Related]
22. Amelioration of negative symptoms in schizophrenia by glycine.
Javitt DC; Zylberman I; Zukin SR; Heresco-Levy U; Lindenmayer JP
Am J Psychiatry; 1994 Aug; 151(8):1234-6. PubMed ID: 8037263
[TBL] [Abstract][Full Text] [Related]
23. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
Cascella NG; Macciardi F; Cavallini C; Smeraldi E
J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
[TBL] [Abstract][Full Text] [Related]
24. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
25. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
26. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder.
de Kleine RA; Hendriks GJ; Kusters WJ; Broekman TG; van Minnen A
Biol Psychiatry; 2012 Jun; 71(11):962-8. PubMed ID: 22480663
[TBL] [Abstract][Full Text] [Related]
27. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
[TBL] [Abstract][Full Text] [Related]
28. D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices.
Rouaud E; Billard JM
Br J Pharmacol; 2003 Nov; 140(6):1051-6. PubMed ID: 14530208
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Nations KR; Smits JA; Tolin DF; Rothbaum BO; Hofmann SG; Tart CD; Lee A; Schipper J; Sjogren M; Xue D; Szegedi A; Otto MW
J Clin Psychiatry; 2012 May; 73(5):647-53. PubMed ID: 22394471
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
[TBL] [Abstract][Full Text] [Related]
31. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
32. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
[TBL] [Abstract][Full Text] [Related]
33. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
34. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
35. The effect of ketamine and D-cycloserine on the high frequency resting EEG spectrum in humans.
Nottage JF; Gabay A; De Meyer K; Herrik KF; Bastlund JF; Christensen SR; Gijsen S; Mehta MA
Psychopharmacology (Berl); 2023 Jan; 240(1):59-75. PubMed ID: 36401646
[TBL] [Abstract][Full Text] [Related]
36. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
Kremer I; Vass A; Gorelik I; Bar G; Blanaru M; Javitt DC; Heresco-Levy U
Biol Psychiatry; 2004 Sep; 56(6):441-6. PubMed ID: 15364042
[TBL] [Abstract][Full Text] [Related]
37. D-cycloserine added to clozapine for patients with schizophrenia.
Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
[TBL] [Abstract][Full Text] [Related]
38. Glutamate signaling in the pathophysiology and therapy of schizophrenia.
Lin CH; Lane HY; Tsai GE
Pharmacol Biochem Behav; 2012 Feb; 100(4):665-77. PubMed ID: 21463651
[TBL] [Abstract][Full Text] [Related]
39. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder.
Litz BT; Salters-Pedneault K; Steenkamp MM; Hermos JA; Bryant RA; Otto MW; Hofmann SG
J Psychiatr Res; 2012 Sep; 46(9):1184-90. PubMed ID: 22694905
[TBL] [Abstract][Full Text] [Related]
40. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
Kushner MG; Kim SW; Donahue C; Thuras P; Adson D; Kotlyar M; McCabe J; Peterson J; Foa EB
Biol Psychiatry; 2007 Oct; 62(8):835-8. PubMed ID: 17588545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
